ArticleInternational urology and nephrology2026
Urinary bacterial spectrum and antibiotic resistance trends at a Urology Clinic in Hungary between 2012 and 2023.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evolution of Antimicrobial Resistance inMicroorganisms · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeWidespread antibiotic use has promoted a concerning rise in bacterial resistance. To counteract this trend and improve the effectiveness of antibiotic treatments, implementing antibiotic stewardship and an active surveillance system is crucial. Our primary aim was to analyze the local urinary bacterial spectrum and antibiotic resistance trends.
methodsAll positive urine culture results (9423) obtained between January 1, 2012 and December 31, 2023 at the Urology Department, University of Szeged were analyzed. Spearman's rank correlation test was then used to examine changes in bacterial spectrum, resistance trends of the five most common bacteria, and incidences of multidrug-resistant strains and nosocomial Clostridioides difficile infections.
resultsThe proportion of Escherichia coli decreased significantly from 53 to 40% (p < 0.001), whereas that of Proteus mirabilis increased from 4 to 6% (p = 0.018). We observed significant decreases in E. coli for amoxicillin/clavulanic acid (p = 0.011), cefuroxime (p = 0.033), and gentamicin (p < 0.001); Enterococcus faecalis for gentamicin (p = 0.002); Klebsiella pneumoniae for amoxicillin/clavulanic acid, cefuroxime, ceftriaxone, ciprofloxacin, gentamicin, and trimethoprim/sulfamethoxazole (p < 0.001); Pseudomonas aeruginosa for ciprofloxacin (p = 0.001) and gentamicin (p = 0.006); and P. mirabilis for amoxicillin/clavulanic acid (p = 0.018) and trimethoprim/sulfamethoxazole (p = 0.022). Only K. pneumoniae showed a significant increase in resistance trends (fosfomycin, p < 0.001). The incidence of extended-spectrum beta-lactamase-producing bacteria decreased significantly from 14.35% to 8.92% (p < 0.001), whereas that of C. difficile infections decreased by two-thirds.
conclusionAntibiotic stewardship based on accurate surveillance can counteract the increasing trend of antibiotic resistance and help manage urinary tract infections in the future, as well as might reduce the incidence of multidrug-resistant strains and C. difficile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.